Resilience and vulnerability in schizophrenia. Interview by Eckert, A. et al.
A research consortium of neurobiologists and psychiatrists led by Professor Anne Eckert aims to 
improve understanding of schizophrenic psychoses, which may lead to novel therapeutic targets
First, could you outline your plan to create 
a stronger understanding of resilience and 
vulnerability in schizophrenia?
In recent years, ideas of the aetiopathogenesis 
of psychotic disorders based on the concept 
of ‘vulnerability’ have been gaining increasing 
ground. The publications of Zubin and 
associates above all have contributed to a 
‘vulnerability stress model’. According to this 
descriptive model, schizophrenic psychoses 
develop as a result of underlying vulnerability, 
which seems to be a genetic one in most 
cases, and triggers such as stress factors 
under modulation of the social and physical 
environment, which fi nally lead to the outbreak 
of frank psychosis. The increased vulnerability 
which gives rise to this is perceived as a 
threshold descensus of the individual towards 
stimuli. Furthermore, multi-causality of 
vulnerability is assumed as the starting point, 
whereby there is the possibility of several 
therapy approaches. 
On the contrary, protective factors against 
the effects of stress might be the key to the 
development of optimal interventions by 
improving resilience and reducing vulnerability. 
Thus, a more favourite disease outcome 
seems to be associated, among others, with 
less vulnerability and greater resilience. The 
vulnerability-resilience model differentiates 
temporarily relatively stable trait markers 
with generally unaltered expressivity at the 
pre-, intra-, and post-psychotic stages in 
contrast to episode (state) markers. The goal 
of the present study is the identifi cation of 
resilience and vulnerability factors using a 
multilevel approach from psychopathology, 
neuropsychology and neuroimaging to 
neurobiology.
Why is it important to look at this disorder 
through different levels: psychopathology, 
neuropsychology and neuroimaging to 
neurobiology ? 
We want to relate disturbances in several 
patient groups in brain structure, brain 
function, information processing, and 
mitochondrial abnormalities at the molecular 
and cellular level to each other and to 
psychopathology in an interdisciplinary 
research setting, addressing a translational 
approach. Linking psychopathology to 
functional aspects of mitochondria and 
brain structure and function might represent 
an advantage with regard to a better 
characterisation of vulnerability and resilience 
factors in patient groups compared to single 
approaches. One important step in taking 
this novel approach is to differentiate and 
characterise trait and state markers for 
schizophrenic psychoses. Psychotic symptoms 
alone are not adequate for determining the 
genetic and neural basis of schizophrenia. 
Future studies should underscore whether 
and to what extent the enduring trait markers 
for these psychoses are modifi able and how 
they are related to state markers for frank 
psychosis. Knowledge acquired from our 
study will eventually be applied to unravel the 
pathophysiology and to inform prevention and 
intervention strategies.
Could you expand on the main methods you 
employ? Have you developed any innovative 
techniques specifi cally for this study? 
Very little is known about the nature 
of structural and neurofunctional brain 
correlations of liability to psychosis. The 
objective of the present project is to develop 
a better understanding of the neurobiological 
mechanisms of liability and resilience factors 
for these disorders. This will be achieved by 
using state of the art neuroimaging methods 
such as Magnetic Resonance Imaging (MRI) 
to examine brain structural and functional 
correlates and correlating them with blood 
biomarker fi ndings. The innovation lies in 
the fact that the team wants to link results 
gained from different innovative techniques 
on an individual level to identify a potentially 
important set of factors that, when combined, 
yield high sensitivity, specifi city, and positive 
predictive value for identifying individuals at 
high risk for schizophrenia.
How important is forming partnerships to 
the success of your research? 
The research team recognises the challenge 
of such a complex project which requires 
collective action, involving a range of 
stakeholders working in partnership. Very 
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SCHIZOPHRENIC PSYCHOSES CAN be 
long-term mental health conditions; the most 
common form being the paranoid type which 
is characterised by the presence of prominent 
delusions or auditory hallucinations. Commonly, 
the onset of schizophrenic psychoses in men 
peaks at around age 20, whereas the onset 
peak is later in women, at around their mid-
twenties. Approximately 4 per cent of all cases of 
schizophrenia experience the onset of the disorder 
before the age of 18. Subtle prodromal symptoms 
frequently present in individuals, on average fi ve 
years prior to onset of frank psychosis. 
It is being increasingly recognised that 
schizophrenia is a pleiotropic disorder. The past 
decade has witnessed an abundance of studies 
focusing on the broad spectrum of different 
psychopathologies (including misinterpretations 
of perceptions or experiences, disorganised 
thinking and behaviour, affective symptoms, but 
also dysfunction in cognition) as well as brain 
structure and function. Magnetic resonance 
spectroscopy has led to a better understanding 
of the disease suggesting that schizophrenia 
is a disease of brain energetics characterised 
by abnormalities in mitochondrial function 
and oxidative stress levels. Although different 
schizophrenia types are similar in symptom 
presentation and many neurobiological aspects, 
there is evidence of different disease variations 
with diverse etiologies and pathomechanisms 
as articulated in the endophenotype concept of 
schizophrenia. Furthermore, there is evidence 
that improved patient outcomes are associated, 
among other things, with less vulnerability and 
greater resilience. 
However, exact pathogenetic mechanisms are 
not yet known, although genetic vulnerability 
seems to underly most disorders. There are 
currently discrepancies in published data, which 
might be the result of investigating different 
patient populations by using different methods, 
e.g. different tissues. For example, in many 
cases investigated, patient groups are not well 
defi ned with regard to factors such as type of 
schizophrenia, course of illness and medication, 
age of onset, impact of gender, and neurobiology. 
WELL-DEFINED PATIENT GROUPS
A team at the University of Basel in Switzerland 
is currently undertaking research designed 
specifi cally to deal with these limitations, 
using well-defi ned and highly specifi c patient 
groups which sets their project apart from all 
previous investigations in this fi eld. Led by 
project coordinator Professor Anne Eckert, the 
consortium’s three co-investigators are: Stefan 
Borgward, MD; Anita Riecher-Rössler, MD; and 
Marc Graf, MD. Funded with a grant from the 
Swiss National Science Foundation, the project 
is a collaboration between the Neurobiology 
Laboratory For Brain Aging and Mental Health 
(Professor Anne Eckert who is responsible for the 
neurobiological methods and biomarker research), 
the Department of Forensic Psychiatry at the 
University (Marc Graf, MD), which deals with the 
most severe forms of schizophrenia, and the FePsy 
(Früherkennung von Psychosen, early detection of 
psychosis) Clinic (Professor Anita Riecher-Rössler). 
This project has established the methodology and 
experience of exactly characterising patients with 
a predisposition to schizophrenia and patients in 
the very early phase of schizophrenia – not only 
in the clinical domain of psychopathology and risk 
factors but also in the domain of neuropsychology 
and neuroimaging (the latter led by Professor 
Stefan Borgwardt).
This unique collaboration opens up a great 
opportunity to study a broad range of patients, 
from individuals with an at-risk mental state, to 
fi rst episode patients and patients with a chronic 
course, as well as age-matched controls. “For the 
fi rst time, a direct comparison between distinct 
patients groups usually merged under the term 
‘schizophrenia’ by using identical laboratory 
methods will be possible,” Eckert reveals.
The project is investigating the patient groups 
and the healthy controls using a multilevel 
approach addressing working hypotheses in 
three areas: neurocognition and resilience; 
neurobiology; and neuroimaging. They are 
aiming to use this interdisciplinary setting 
to relate disturbances in brain structure and 
function, psychopathology and information 
processing with abnormalities in energetic 
homeostasis. The research is expected to 
contribute to a better understanding of resilience 
and vulnerability factors in schizophrenia than 
has previously been achieved.
THE CORE HYPOTHESIS
An important hypothesis is the question of 
whether an increase of cognitive defi cits is related 
to an increased vulnerability and a reduced 
resilience as expressed by abnormalities in cellular 
energetics and/or structural and neurofunctional 
abnormalities. The investigators will verify this 
hypothesis by using a neuropsychological test 
Sculpting schizophrenia
Work underway at the University of Basel in Switzerland takes an 
unprecedented approach to understanding schizophrenic psychoses by 
combining neurobiological methods, neuroimaging, neuropsychological 
and clinical methods to investigate well-defi ned patient groups
important national collaborations have 
been established with the Medical Image 
Analysis Centre (MIAC); the Departments 
of Radiological Physics and Department of 
Neuroradiology of the University Hospital 
Basel (Ernst-Wilhelm Radü and Christoph 
Stippich); and with the Interdepartmental 
Research Platform of the University of Basel 
(Andreas Papassotiropoulos). Internationally, 
close collaborations exist with King’s College 
London (Philip K McGuire) for development 
of new imaging methods as well as with the 
Department of Pharmacology, University of 
Frankfurt (Walter E Müller) for the optimisation 
of biomarker research with the focus on 
bioenergetics.
What ultimate impacts do you hope the 
project has?
This study should clarify the understanding of 
the pathogenetic mechanisms of schizophrenic 
psychoses with respect to vulnerability and 
resilience factors. Increased understanding 
of these pathophysiological mechanisms 
may lead to novel therapeutic targets for 
schizophrenic psychoses.
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FIGURE 1. Structural neuroimaging in prodromal psychosis, gray matter reductions associated with vulnerability and 
transition to psychosis. Gray matter probability maps for comparison of all subjects with an At-Risk Mental State (ARMS), 
fi rst-episode patients and healthy controls.
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battery, which covers the domains of general 
intelligence, executive functions, memory and 
attention as well as the Resilience and Social 
and Functioning Assessment Scale. The aim of 
this part of the study is to compare the profi le 
and severity of cognitive defi cits indicating 
vulnerability or resilience in patients with chronic 
schizophrenia, fi rst episode schizophrenia as well 
as in at-risk mental state.
For neurobiology, on the basis of current research 
and the consortium’s preliminary study fi ndings, 
the group expects changes in mitochondrial 
function as well as abnormalities in oxidative 
stress and energy levels to be found in blood 
cells of all these patients. This hypothesis will 
be verifi ed by using a combined approach 
ranging from gene profi ling to functional aspects 
of mitochondria. Lymphocytes are not only 
easily accessible but, unlike postmortem brain 
tissue, can also be subjected to experimental 
manipulations. The work will also go beyond 
gene expression profi ling from freshly drawn 
blood to culture lymphocytes of patients and 
healthy controls under stress conditions related 
to energy homeostasis. This approach will allow 
for a more comprehensive view of the complex 
interplay between genes and cellular function, 
and give way to characterising patterns of 
mitochondrial vulnerability and resilience in 
blood cells from different schizophrenic patient 
groups.
It has recently been accepted that schizophrenia 
is associated with neuroanatomical 
abnormalities. However, the extent to which 
these are related to the vulnerability of the 
disorder, rather than the illness itself, is less 
certain. Within the FePsy project it has recently 
been shown for the area of neuroimaging that 
subjects with an at-risk mental state show brain 
structural and neurofunctional abnormalities 
relative to controls that are qualitatively 
similar to those in patients with fi rst episode 
schizophrenia and that these abnormalities 
progress with transition to frank psychosis. In 
this project the scientists can now compare 
them to chronic patients with schizophrenia 
and expect to fi nd a linear trend for more 
structural and neurofunctional abnormalities. 
Furthermore, and most importantly, they can 
correlate these neuroanatomical with the 
corresponding biomarker fi ndings.
UNDERSTANDING SCHIZOPHRENIA
By the end of the project, four main aims 
are expected to be addressed: identifi cation 
of resilience and vulnerability factors that 
are specifi c for a single patient collective; 
identifi cation of differences or similarities 
between the different patient groups versus 
controls; characterisation of associations 
between parameters of brain structure 
and function, defects in mitochondria 
and failure in bioenergetics demands and 
psychopathology; and characterisation of 
putative endophenotypes.
This collaborative project provides a unique 
approach to understanding schizophrenia, 
especially because links between 
psychopathology and functional aspects 
of mitochondria and brain structure and 
function assessed by structural and functional 
MRI with specifi c regard to vulnerability 
and resilience factors in schizophrenia have 
never been documented before. Determining 
the mechanisms of structural and neural 
abnormalities will hopefully improve knowledge 
of the processes that are implicated in biological 
vulnerability or resilience to mental illness. 
In the long term it is hoped that the study 
will contribute to clear rationales for specifi c 
treatments aimed at improving brain energy 
metabolism in disorders like schizophrenia.
VULNERABILITY AND RESILIENCE 
FACTORS OF SCHIZOPHRENIA: AN 
APPROACH COMBINING NEUROIMAGING, 
NEUROPSYCHOLOGICAL AND 
NEUROBIOLOGICAL METHODS
OBJECTIVES
•  To relate disturbances in patient groups with 
schizophrenic psychoses in brain structure and 
function, with mitochondrial abnormalities at 
the molecular and cellular level
•  Characterisation of associations between 
parameters of brain structure and function, 
defects in mitochondria and energy 
homeostasis and psychopathology
•  Identifi cation of resilience/vulnerability factors 
in different patient collectives
•  Characterisation of putative endophenotypes
KEY COLLABORATORS
Professor Klaus Schmeck, Kinder- und 
Jugendpsychiatrische Klinik, Psychiatric 
University Clinics • Professor Andreas 
Papassotiropoulos, Division of Molecular 
Psychology, University of Basel • Professor 
Walter E Müller, Department of Pharmacology, 
Biocenter, University of Frankfurt am Main • 
Professor Ernst-Wilhelm Radü, Medical Image 
Analysis Centre (MIAC) and Professor Christoph 
Stippich, Department of Neuroradiology of the 
University Hospital Basel • Professor Philip K 
McGuire, King’s College London, Institute of 
Psychiatry
FUNDING
Swiss National Science Foundation (SNF) grant 
no. 320030_122572
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Project Leader
Psychiatrische Universitätsklinik
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For the fi rst time, a direct comparison between distinct patients groups 
usually merged under the term ‘schizophrenia’ will be possible
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